Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Aduro Biotech Europe

Aduro Biotech Europe
2011 FOUNDED
M&A STATUS
21-30 EMPLOYEES
M&A LATEST DEAL TYPE
$64.6M LATEST DEAL AMOUNT
Description

Provider of therapeutic services for cancer. The company specializes in the development of oncology antibodies for the treatment of cancer.

Formerly Known As
BioNovion
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Services
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
  • Pivot Park, RX1101
  • Molenweg 79
  • 5349 AC OSS
  • Netherlands
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Aduro Biotech Europe’s full profile, request a free trial.

Aduro Biotech Europe Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 30-Oct-2015 $64.6M 000.00 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Aduro Biotech Europe Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Agri Food Health Innovation Centre Venture Capital Minority 000 0000 000000 0
Brabant Life Sciences Seed Fund Venture Capital Minority 000 0000 000000 0
Brabantse Ontwikkelings Maatschappij Venture Capital Minority 000 0000 000000 0

Aduro Biotech Europe Executive Team (3)

Name Title Board
Seat
Contact
Info
Wiebe Olijve Ph.D Co-Founder & Chief Executive Officer
Hans Van Eenennaam Ph.D Co-Founder & Chief Operational Officer
Andrea Van Elsas Ph.D Co-Founder & Chief Scientific Officer